• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ATEC Announces Proposed Convertible Senior Notes Offering

    3/3/25 4:00:00 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care
    Get the next $ATEC alert in real time by email

    Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced its intention to offer, subject to market and other conditions, $300,000,000 aggregate principal amount of convertible senior notes due 2030 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). ATEC also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $50,000,000 principal amount of notes.

    The notes will be senior, unsecured obligations of ATEC, will accrue interest payable semi-annually in arrears and will mature on March 15, 2030, unless earlier repurchased, redeemed or converted. Before September 17, 2029, noteholders will have the right to convert their notes only upon the occurrence of certain events. From and after September 17, 2029, noteholders may convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. ATEC will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at ATEC's election, subject to certain restrictions. The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at ATEC's option at any time, and from time to time, on or after March 20, 2028 and on or before the 60th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of ATEC's common stock exceeds 130% of the conversion price for a specified period of time and certain other conditions are satisfied. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. If certain events that constitute a "fundamental change" occur, then, subject to a limited exception, noteholders may require ATEC to repurchase their notes at a cash repurchase price equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date. The final terms of the notes, including the interest rate, initial conversion rate and certain other terms of the notes, will be determined at the pricing of the offering.

    In connection with the pricing of the notes, ATEC expects to enter into one or more privately negotiated capped call transactions with one or more of the initial purchasers of the notes and/or their respective affiliates and/or other financial institutions (in this capacity, the "option counterparties"). The capped call transactions are expected generally to reduce the potential dilution to ATEC's common stock upon any conversion of the notes and/or offset any cash payments ATEC is required to make in excess of the principal amount of the converted notes, as the case may be, with such reduction and/or offset subject to a cap. If the initial purchasers of the notes exercise their option to purchase additional notes, ATEC expects to enter into additional capped call transactions with the option counterparties.

    ATEC has been advised that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to enter into various derivative transactions with respect to ATEC's common stock and/or purchase shares of ATEC's common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of ATEC's common stock or the notes at that time.

    In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to ATEC's common stock and/or purchasing or selling shares of ATEC's common stock or other of ATEC's securities in secondary market transactions following the pricing of the notes and from time to time prior to the maturity of the notes (and are likely to do so following any conversion of the notes, any repurchase of the notes by ATEC on any fundamental change repurchase date, any redemption date or any other date on which the notes are retired by ATEC, in each case if ATEC exercises the relevant election under the capped call transactions where such termination is at ATEC's option). This activity could also cause or avoid an increase or a decrease in the market price of ATEC's common stock or the notes, which could affect the ability of holders of the notes to convert the notes and, to the extent the activity occurs during any observation period related to a conversion of notes, it could affect the number of shares of ATEC's common stock and value of the consideration that holders of notes will receive upon conversion of such notes.

    ATEC intends to use (i) a portion of the net proceeds from the offering to fund the cost of entering into the capped call transactions; (ii) a portion of the net proceeds from the offering to repurchase and cancel a portion of its outstanding 0.75% convertible senior notes due 2026 (the "2026 notes") in privately negotiated transactions concurrently with the pricing of the offering; and (iii) the remainder of the net proceeds from the offering for general corporate purposes. If the initial purchasers exercise their option to purchase additional notes, then ATEC intends to use a portion of the additional net proceeds to fund the cost of entering into additional capped call transactions.

    Holders of the 2026 notes that are repurchased in the concurrent repurchases described above may purchase shares of ATEC's common stock in the open market to unwind any hedge positions they may have with respect to the 2026 notes. These activities may affect the trading price of ATEC's common stock and, if conducted concurrently with the offering, may result in a higher initial conversion price for the notes ATEC is offering.

    The notes will be offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of common stock issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

    About ATEC

    ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC's Organic Innovation MachineTM is focused on developing new approaches that integrate seamlessly with the Company's expanding AlphaInformatiX Platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC's vision is to become the Standard Bearer in Spine.

    Special Note on Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated terms of the notes being offered, the completion, timing and size of the proposed offering, the intended use of the net proceeds, the anticipated terms of, and the effects of entering into, the capped call transactions described above and the actions of the option counterparties and their respective affiliates and the anticipated terms of, and the effects of entering into, the repurchases of 2026 notes described above. These statements reflect ATEC's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause ATEC's actual results, performance or achievements to differ materially from those expressed in, or implied by, such statements. These risks, uncertainties, factors and contingencies include, but are not limited to: market conditions, including market interest rates, the trading price and volatility of ATEC's common stock and risks relating to ATEC's business, including those described in periodic reports that ATEC files from time to time with the Securities and Exchange Commission. ATEC may not consummate the proposed offering described in this press release and, if the proposed offering is consummated, cannot provide any assurances regarding the final terms of the offer or the notes or its ability to effectively apply the net proceeds as described above. All information in this release is as of the date hereof, and ATEC undertakes no obligation to update any forward-looking statement to conform the statement to actual results or changes in ATEC's expectations, except as may be required by law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250303198116/en/

    Investor/Media Contact:

    Tina Jacobsen, CFA

    Investor Relations

    (760) 494-6790

    [email protected]

    Company Contact:

    J. Todd Koning

    Chief Financial Officer

    Alphatec Holdings, Inc.

    [email protected]

    Get the next $ATEC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ATEC

    DatePrice TargetRatingAnalyst
    6/16/2025$18.00Buy
    Lake Street
    8/1/2024Overweight → Equal-Weight
    Morgan Stanley
    7/8/2024$19.00Overweight
    Barclays
    2/9/2024$26.00Overweight
    Wells Fargo
    12/19/2023$16.00 → $18.00Buy
    Needham
    10/20/2023$22.00Buy
    ROTH MKM
    10/12/2022$12.00Buy
    Jefferies
    9/12/2022$13.00Overweight
    Morgan Stanley
    More analyst ratings

    $ATEC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • iRhythm Technologies Announces Board Member Retirements and New Director Appointments

      SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O'Boyle have accepted appointments to the board of directors. Mark Rubash has served on the board since 2016, prior to the company's initial public offering, bringing decades of experience in finance, accounting, and strategy at high-growth technology companies. Ralph Snyderman, M.D., who joined the board in 2017, br

      7/7/25 8:30:00 AM ET
      $ABSI
      $ATEC
      $ILMN
      $IRTC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Medical/Dental Instruments
      Medical Specialities
    • ATEC Reports First Quarter 2025 Financial Results and Raises Full-Year Guidance

      Surgical revenue grew 24%; total revenue grew 22% Full-year revenue and profitability guidance increased Successfully refinanced convertible debt to 2030 maturity Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended March 31, 2025, and recent corporate highlights. First Quarter 2025 Financial Results   Quarter Ended March 31, 2025 Total revenue $169 million GAAP gross margin 69% Non-GAAP gross margin 70% GAAP operating expenses $160 million Non-GAAP operating expenses $124 million GAAP net income /

      5/1/25 4:05:00 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • ATEC Launches PTP™ Corpectomy, The Next Evolution of Lateral Approach Surgery

      Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced the commercial launch of its Prone TransPsoas (PTP™) Corpectomy system. This milestone marks the continued evolution of ATEC's PTP surgical approach, expanding its capabilities to include deformity and corpectomy procedures for complex pathologies of the thoracolumbar spine. "PTP Corpectomy represents a significant step forward in ATEC's commitment to improving patient outcomes in the most complex spine surgeries," said Pat Miles, Chairman and Chief Executive Officer. "By integrating advanced surgical techniques within a fully proceduralized

      4/21/25 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    SEC Filings

    See more
    • SEC Form S-8 filed by Alphatec Holdings Inc.

      S-8 - Alphatec Holdings, Inc. (0001350653) (Filer)

      6/13/25 4:46:41 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Alphatec Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Alphatec Holdings, Inc. (0001350653) (Filer)

      6/13/25 4:03:07 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Alphatec Holdings Inc.

      144 - Alphatec Holdings, Inc. (0001350653) (Subject)

      6/11/25 11:15:31 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bakst Evan bought $201,600 worth of shares (35,000 units at $5.76) (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      8/26/24 4:32:07 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Director Pelizzon David R bought $149,998 worth of shares (25,796 units at $5.81), increasing direct ownership by 8% to 331,696 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      8/26/24 4:27:25 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Director Demski David M bought $283,500 worth of shares (50,000 units at $5.67), increasing direct ownership by 21% to 288,441 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      8/21/24 10:00:00 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF OPERATING OFFICER Lish Scott sold $251,588 worth of shares (22,727 units at $11.07), decreasing direct ownership by 3% to 748,918 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      6/17/25 6:00:06 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Director Woods Ward W Jr was granted 15,131 shares, increasing direct ownership by 11% to 154,291 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      6/13/25 5:30:17 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Director Valentine Keith was granted 15,131 shares, increasing direct ownership by 18% to 97,271 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      6/13/25 5:30:16 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Leadership Updates

    Live Leadership Updates

    See more
    • Paragon 28 Appoints Dave Demski to Board of Directors

      Paragon 28, Inc. (NYSE:FNA), (the "Company") a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities. Mr. Demski most recently served as the President and CEO of Globus Medical from August 2017 to April 2022, guiding the organization through a period of signifi

      12/11/24 9:00:00 AM ET
      $ATEC
      $FNA
      Medical/Dental Instruments
      Health Care
    • Spineology® Appoints new Member to Leadership Team; Spine Veteran Emory Rooney joins as Executive Vice President of Sales

      Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales. In this role, Rooney will lead U.S. market growth and sales efforts. Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years. "The addition of Emory adds even further conviction about our clear opportunity for growth at Spineology," said Brian Snider, Chief Executive Officer at Spineology. "I have had the opportunity to work with Emory and have seen his impact leading sales teams, building new terri

      4/4/24 9:05:00 AM ET
      $ATEC
      $SYK
      Medical/Dental Instruments
      Health Care
    • John Booth to Retire as CEO of Spineology Inc.

      Brian Snider Appointed New CEO Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today that John Booth will retire from his role as Chief Executive Officer of Spineology, effective November 10, 2023. The Board of Directors has selected Brian Snider as its next Chief Executive Officer, effective November 13, 2023. Mr. Booth will remain with Spineology through 2024, serving in an advisory role to facilitate a smooth transition. Mr. Booth will also resign from the Board of Directors, and the Board has nominated Mr. Snider as a Director. Snider joins Spineology with nearly twenty years of progressive leadership experience in the

      11/9/23 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Financials

    Live finance-specific insights

    See more
    • ATEC to Report First Quarter 2025 Financial Results on May 1, 2025

      Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report first quarter 2025 financial results on May 1, 2025, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-In To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. Inducemen

      4/14/25 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • ATEC to Report Third Quarter Financial Results on October 30, 2024

      Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report third quarter 2024 financial results on October 30, 2024, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-in To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. Indu

      10/7/24 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • ATEC to Report Second Quarter Financial Results on July 31, 2024

      Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report second quarter 2024 financial results on July 31, 2024, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-in To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months.

      7/10/24 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street resumed coverage on Alphatec with a new price target

      Lake Street resumed coverage of Alphatec with a rating of Buy and set a new price target of $18.00

      6/16/25 8:53:19 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Alphatec downgraded by Morgan Stanley

      Morgan Stanley downgraded Alphatec from Overweight to Equal-Weight

      8/1/24 3:06:35 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Barclays initiated coverage on Alphatec with a new price target

      Barclays initiated coverage of Alphatec with a rating of Overweight and set a new price target of $19.00

      7/8/24 7:34:11 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Alphatec Holdings Inc.

      SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

      11/12/24 8:04:57 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Alphatec Holdings Inc. (Amendment)

      SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

      3/22/24 7:57:56 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Alphatec Holdings Inc. (Amendment)

      SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

      5/12/23 4:51:18 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care